Company / Cash & Equivalents
TELA Bio, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$50.8M
FY2025
5-year range
$42.0M / $52.7M
FY2021-FY2025
Trend
-3.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $47M to $51M over the past 2 years.
Based on SEC 10-K filings.
$51M in FY2025 with a 5-year CAGR of +2.3%.
Improved from $47M to $51M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +6.6%
- 5-Year CAGR
- +2.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +2.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 3.5% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.8M | -3.5% |
| FY2024 | $52.7M | +12.7% |
| FY2023 | $46.7M | +11.2% |
| FY2022 | $42.0M | -4.4% |
| FY2021 | $43.9M | -3.0% |
| FY2020 | $45.3M | +0.0% |
| FY2019 | $45.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026